# Onasis


## Posts

- [Onassis Holdings Retained Investment Bank Dalmore Group to Launch up to $75 Million Regulation A+ Offering (Mini IPO)](https://www.onassis-holdings.com/onassis-holdings-retained-investment-bank-dalmore-group-to-launch-up-to-75-million-regulation-a-offering-mini-ipo/): Onassis is about to launch a Reg D 506c to raise funds from US accredited investors Dalmore Group&#8217;s  has more th a n $2B raised by issuers and more than 1,000,000 processed NEW YORK, Sept. 15, 2025 /PRNewswire/ &#8212; Onassis Holding Corp (OTC: ONSS), a biotech focused holding company, announced the launch of a Regulation A+ financing round. This follows an agreement with Dalmore Group. Onassis Holdings Corp Logo Reg A+ provides a streamlined process for companies to raise up to $75 million annually from the public. In aligning with Dalmore Group, Onassis looks to leverage the investment bank&#8217;s prowess in capital raising through Regulations A+, CF, and D. Since 2021, Dalmore has [&hellip;]

## Pages

- [Esq. Paz Itzhaki-Weinberger](https://www.onassis-holdings.com/esq-paz-itzhaki-weinberger/): Esq. Paz Itzhaki-Weinberger International law advisor Paz has vast work experience in the hi-tech industry, working for industry leaders such as Microsoft Corporation and managing hi-tech firms. As a person with a combination of Engineering and law (also a practicing Lawyer), Paz has been practicing law at Israel&#8217;s most prestigious law firm in the fields of rehabilitation and liquidation of companies, and founded PIWLAW firm who was ranked as one of the top 200 law firms in the world for 2014-2025 by Legals Finest and earned other international law awards. He currently acts as the CEO &amp; Chairman of IWC [&hellip;]
- [Rudolf Jaenisch](https://www.onassis-holdings.com/rudolf-jaenisch/): Prof. Rudolf Jaenisch​ Advisor Rudolf Jaenisch, M.D. Professor of Biology at MIT and Founding Member of the Whitehead Institute for Biomedical Research Rudolf Jaenisch is a pioneering figure in the field of transgenic science, renowned for his groundbreaking work in genetic modification and epigenetic research. As a professor of biology at the Massachusetts Institute of Technology (MIT) and a founding member of the Whitehead Institute for Biomedical Research, Jaenisch has made numerous contributions to our understanding of cancer, neurological diseases, and the mechanisms of gene expression. Jaenisch&#8217;s seminal work began in 1974, when he and his colleague Beatrice Mintz made [&hellip;]
- [Dr. Guy Shalom Shraga ](https://www.onassis-holdings.com/dr-guy-shalom-shraga/): Dr. Guy Shalom Shraga  Medical advisor for dermatology Dr. Shalom is an accomplished dermatologist with extensive experience in both clinical practice and academic research. He holds a BSc and MD from Ben-Gurion University of the Negev, where he graduated with honors. With board certification in dermatology and a specialty in advanced dermatologic technologies, Dr. Shalom has made significant contributions to the fields of teledermatology and dermatologic research. He currently serves as the Director of the National Teledermatology Service for Clalit Health Services in Israel and is recognized for his work on the epidemiology of chronic skin conditions, including psoriasis and [&hellip;]
- [Dr. Justin West-Newport beach California](https://www.onassis-holdings.com/dr-justin-west-newport-beach-california/): Dr. Justin West-Newport beach, California Strategic medical advisor  Dr. West is a board-certified plastic surgeon based in Newport Beach, California. He holds a BA in biology from Pomona College and earned his medical degree from Thomas Jefferson University. Dr. West completed his residency in Plastic and Reconstructive Surgery at Georgetown University Hospital and advanced fellowship training at Manhattan Eye Ear and Throat Hospital. He has served as the Director of Plastic and Reconstructive Surgery for Breastlink Medical Group and is the founder and Medical Director of Finesse Plastic Surgery. Renowned for his patient-focused care, Dr. West attracts patients nationally and [&hellip;]
- [Ford Seeman](https://www.onassis-holdings.com/ford-seeman/): Ford Seeman Director Ford Seeman is a seasoned business development and investment strategist. With a strong foundation in financial analysis from his time as an associate at a boutique investment bank, he brings a wealth of experience to his role as a Director. Mr. Seeman’s expertise will be instrumental in guiding the company’s strategic direction. Mr. Seeman currently serves as an advisor or board member to 8 companies. His network will be extremely valuable to leverage as we rapidly advance and evolve. We want to hear from you. Contact Us Privacy Policy Terms of Service © 2024 Ananda Labs. All [&hellip;]
- [Roby Zomer](https://www.onassis-holdings.com/roby-zomer/): Roby Zomer COO Roby Zomer, with over a decade of experience in the BioTech and AgroTech sectors, he has established himself as a seasoned professional adept at navigating the complexities of these dynamic industries. His career encompasses the successful management of large-scale projects, where he has demonstrated exceptional leadership and organizational skills. His extensive business network, cultivated through years of strategic partnerships and collaborations, underscores his ability to connect with key stakeholders across various sectors. In addition to his business acumen, he brings a deep understanding of scientific and engineering principles, which enables him to bridge the gap between technical [&hellip;]
- [Anat Malkin](https://www.onassis-holdings.com/anat-malkin/): Anat Malkin, Esq., Attorney &#038; Entrepreneur VP Business Development Anat Malkin is a distinguished attorney, educated in both the UK and Israel. Alongside her legal career, she has proven herself as a successful entrepreneur, founding several companies across various industries. With extensive experience in marketing and a deep expertise in internet-based businesses, Anat has built a robust international network. She is now set to lead the global business development efforts for Onassis Holdings Corp, leveraging her unique skills and connections to drive the company’s growth around the world. We want to hear from you. Contact Us Privacy Policy Terms of [&hellip;]
- [Eyal G.](https://www.onassis-holdings.com/eyal-g/): Dr. Eyal G Co-Founder, CTO Dr. G earned his Ph D. from the Weizmann Institute of Science, specializing in cancer research. With over 14 years of experience in the biotechnology industry, Dr. G has led various R&amp;D projects from concept through to clinical phases in the pharmaceutical and medical diagnostics fields. During this time, he has overseen numerous development programs focusing in Discovery, Non-clinical development, regulatory compliance with the FDA, process development, chemistry, manufacturing and controls (CMC), and Safety. We want to hear from you. Contact Us Privacy Policy Terms of Service © 2024 Ananda Labs. All rights reserved.
- [Chairman](https://www.onassis-holdings.com/chairman/): We want to hear from you. Contact Us Privacy Policy Terms of Service © 2024 Ananda Labs. All rights reserved.
- [Our Team](https://www.onassis-holdings.com/our-team/): Team Leadership Our skilled team Prof. Yosef Buganim Co-Founder, CSO Dr. Eyal G Co-Founder, CTO Anat Malkin, Esq. VP Business Development Roby Zomer COO Ford Seeman Director Dr. Justin West Strategic medical advisor Dr. Guy Shalom Shraga Medical advisor for dermatology Esq. Paz Itzhaki-Weinberger International law advisor Prof. Rudolf Jaenisch Advisor
- [Prof. Yossi Buganim Bio.](https://www.onassis-holdings.com/yossi-buganim/): Prof. Yosef (Yossi) Buganim Co-Founder, CSO Prof. Buganim is an associate professor at the faculty of medicine at the Hebrew University of Jerusalem. Buganim received his undergraduate degrees from Bar-Ilan University and a Ph.D. degree from Weizmann Institute of Science. His postdoctoral training on nuclear reprogramming techniques he conducted at the Whitehead Institute for Biomedical Research, MIT. Buganim was the first to generate induced pluripotent stem cells (iPSCs) without “Yamanaka’s factors” and his own group is pioneering the conversion of skin cells into placental stem cells and was the first to demonstrate the induction of all the three early embryo [&hellip;]
- [Opportunities page](https://www.onassis-holdings.com/opportunities-page/): Investors Invest in the future of medicine If you&#8217;re interested in investing in the forefront of rapidly advancing longevity medicine and being among the pioneers globally, please contact us at: Info@ananda-labs.com Business Development Collaborating with Ananda Ananda values the importance of collaboration and believes our platform can greatly benefit other businesses. We are open to discussing potential partnerships with biotech, lifestyle, and cosmetic companies that could enhance our research and development in combating degenerative diseases and age-related conditions affecting billions globally. For collaboration inquiries, please contact  us   bizdev@ananda-labs.com Careers We are  dedicated to improving life for people with incurable degenerative [&hellip;]
- [Terms of use](https://www.onassis-holdings.com/terms-of-use/): Site terms &#038; Conditions Last updated: August 2017 1. Privacy Please review our Privacy Policy (Appended to these Terms &amp; Conditions), which also governs your visit to our Site, to understand our practices. When using our Site, you are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept full responsibility for all activities that occur under your account or password. You agree to notify us immediately of any unauthorized access or use of your account or password or any other breach of security. You understand that any person [&hellip;]
- [Ask Our AI page](https://www.onassis-holdings.com/ask-our-ai-page/): Next page: Video Coming Soon We want to hear from you. Contact Us Privacy Policy Terms of Service © 2024 Onassis Holdings Corp. All rights reserved.
- [Scientific publications online](https://www.onassis-holdings.com/scientific-publications-online/): Previous page: Scientific publications list Scientific Publications in PubMed  01 &#8211; Unlocking trophectoderm mysteries: In vivo and in vitro perspectives on human and mouse trophoblast fate induction 02 &#8211; Complex Haploinsufficiency in Pluripotent Cells Yields Somatic Cells with DNA Methylation Abnormalities and Pluripotency Induction Defects 03 &#8211; Pluripotency-independent Induction of Trophoblast Stem Cells from Human Fibroblasts 04 &#8211; Comparative Parallel Multi-Omics Analysis of Cell Undergoing Reprogramming to Pluripotent and Trophectoderm States 05 &#8211; Direct Induction of the Three Pre-Implantation Blastocyst Cell Types from Fibroblasts 06 &#8211; Back to Basics: Refined Nuclear Reprogramming Techniques Yield Higher-Quality Stem Cells 07 &#8211; Nuclear [&hellip;]
- [Video](https://www.onassis-holdings.com/video/): Next page: Scientific publications list https://onassis-holdings.com/wp-content/uploads/2024/06/2034-4fe4-86be-0e134bf0161f-1.mov We want to hear from you. Contact Us Privacy Policy Terms of Service © 2024 Onassis Holdings Corp. All rights reserved.
- [About us](https://www.onassis-holdings.com/about-us/): https://onassis-holdings.com/wp-content/uploads/2024/06/about_1.mp4 Mission Cellular Rejuvenation: Once a Dream, Now Our Mission  Aging is a process accompanied by progressive decline in cellular function. Our aim is to create a groundbreaking therapy based on patented proteins, that rejuvenate elderly cells, all while maintaining their distinct properties. innovative research Introduction Onassis Holdings Corp is a company dedicated to finding, investing in, and developing solutions for regenerative medicine, longevity, rejuvenation, and anti-aging. Currently, it operates a subsidiary named Ananda Labs, Inc., a U.S. startup headquartered in New York City with an office in Tel Aviv. Established in 2023, Ananda Labs has developed the RPER platform, [&hellip;]
- [Pipeline](https://www.onassis-holdings.com/pipeline/): https://onassis-holdings.com/wp-content/uploads/2024/07/a31a-4dd1-af74-5315f8fba176.mp4 rejuvenating Pipeline At Ananda Labs, our unique set of factors, refined over a decade of research, allows us to develop personalized therapies for a wide range of age-related diseases and conditions, impacting billions worldwide. Unlike most treatments that merely alleviate symptoms, our goal is to address the root causes of these conditions. We focus on rejuvenating the immune system, restoring vision, and improving skin health to combat issues such as wrinkles, skin damage, and hair loss. Our cutting-edge pipeline aims to achieve what current medicine cannot—curing or significantly treating conditions once deemed incurable. Pipeline Our Mission in Dermal Treatments [&hellip;]
- [Scientific publications list](https://www.onassis-holdings.com/scientific-publications-list/): Next page: Scientific publications online PUBLICATIONS Impactful Publications &nbsp;For the past 10 years, the Buganim Lab has been dedicated to studying and investigating the process of epigenetic reprogramming. Our research has led to the identification of multiple gene combinations that can reshape the epigenetic landscape of cells, converting them into embryonic and placental stem cells. In addition to developing our own technology for this epigenetic reshaping, we also focus extensively on understanding the underlying mechanisms that enable this process. Below is a selected list of publications that highlight our work in epigenetic reprogramming. Unlocking trophectoderm mysteries: In vivo and in [&hellip;]
- [Contact Us](https://www.onassis-holdings.com/contact-us/): contact Contact Us Our team is available to offer additional details  regarding products and services, or to address any  ongoing issues and more. Ananda Labs, Inc.39 BroadwaySTE 3010New York, NY 10006info@ananda-labs.com516-620-6794 Global Locations Add Your Tooltip Text Here Add Your Tooltip Text Here Add Your Tooltip Text Here
- [Investor news](https://www.onassis-holdings.com/investor-news/)
- [Our Technology](https://www.onassis-holdings.com/our-technology/): Next page: Ask our AI any related question The Problem of Aging Aging Population In the United States, one of the most consistently growing age groups is the 65+ demographic, driven by declining birth rates and breakthroughs in medical science and technology. It is projected that by 2060, this segment will comprise nearly 25% of the entire U.S. population. By the year 2034, for the first time ever, the number of elderly adults is expected to surpass the number of children, significantly affecting the availability of both family and community care resources. With an aging population, there will be an [&hellip;]
- [Science](https://www.onassis-holdings.com/science/): Next page: The problem of aging Our Science The Problem of Aging Decline of Function Aging causes a widescale disruption to the functioning of the human body. As people get older their organs begin to struggle with the basic processes to keep them alive and well. Although the general process of aging affects all tissues, this degeneration does not occur at the same rate throughout the population or even throughout the body. For example, whereas the skeletal muscles begin aging in the 40s, the cells in the lining of the gut do not begin to show signs of aging until [&hellip;]
- [Home](https://www.onassis-holdings.com/): We reverse the clock on&nbsp;age-related&nbsp;conditions development Who we are? A New York-based biotech holding company focused on investing in and developing solutions for anti-aging through epigenetic reprogramming and other methods. Read More https://onassis-holdings.com/wp-content/uploads/2024/07/Ananda-Labs-video-V2.mp4 Revolutionary Our Mission Our mission is to develop treatments that reverse aging-related diseases, rejuvenate appearance for a younger look, and improve the function of the immune system as preventive medicine. technology Science After a decade of intensive university research, we have developed a groundbreaking set of factors that we believe surpass existing technologies. These factors, derived from placental stem cell genes, can effectively modify the epigenetic landscape [&hellip;]


[comment]: # (Generated by Hostinger Tools Plugin)